Shares of Waldencast PLC (NASDAQ:WALD – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the six brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $4.4167.
WALD has been the subject of a number of research analyst reports. Canaccord Genuity Group cut their price target on Waldencast from $5.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, November 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Waldencast in a research note on Wednesday, January 21st. Telsey Advisory Group downgraded shares of Waldencast from an “outperform” rating to a “market perform” rating and set a $3.00 price target for the company. in a report on Tuesday, November 25th. Finally, Jefferies Financial Group started coverage on shares of Waldencast in a report on Wednesday, January 14th. They set a “buy” rating and a $2.00 price objective on the stock.
View Our Latest Stock Analysis on WALD
Hedge Funds Weigh In On Waldencast
Waldencast Stock Down 4.4%
Shares of NASDAQ:WALD opened at $1.74 on Monday. The company has a quick ratio of 0.67, a current ratio of 1.53 and a debt-to-equity ratio of 0.32. The stock’s 50-day moving average is $1.78 and its 200-day moving average is $1.88. Waldencast has a 52-week low of $1.45 and a 52-week high of $3.54.
Waldencast (NASDAQ:WALD – Get Free Report) last posted its quarterly earnings data on Monday, November 24th. The company reported ($0.69) earnings per share for the quarter. The company had revenue of $66.14 million during the quarter. On average, sell-side analysts forecast that Waldencast will post -0.14 earnings per share for the current fiscal year.
About Waldencast
Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians. The company also offers clean makeup products under the Milk Makeup brand. It sells its products to dermatologists, plastic surgeons, and other physicians who focuses on aesthetic and therapeutic skincare, including physicians on site at medical spas, through its direct sales force, as well as through distribution partners.
Read More
- Five stocks we like better than Waldencast
- Your Bank Account Is No Longer Safe
- Nvidia CEO Issues Bold Tesla Call
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
Receive News & Ratings for Waldencast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waldencast and related companies with MarketBeat.com's FREE daily email newsletter.
